| ALGN |
Report |
Total revenue (Q2'26) |
BEAT |
pred ~$1.062B vs. cons ~$1.05B |
MEDIUM |
| ALGN |
Report |
Clear Aligner volume (Q2'26) |
BEAT |
pred ~697K cases vs. cons ~690K |
MEDIUM |
| ALGN |
Report |
Non-GAAP EPS (Q2'26) |
BEAT |
pred ~$2.73 vs. cons ~$2.64 |
MEDIUM |
| ALGN |
Guide |
FY2026 revenue growth guide |
UNCHANGED |
guide ~+3-4% YoY reaffirmed vs. cons ~+3.9% (FY2026) |
MEDIUM |
| ALGN |
Guide |
FY2026 non-GAAP operating margin guide |
UNCHANGED |
guide ~23.7% reaffirmed vs. cons ~23.7% (FY2026) |
MEDIUM |
| ALGN |
Guide |
Q3'26 revenue guide |
UNCHANGED |
guide ~$1.05-1.07B vs. cons ~$1.06B (Q3'26) |
LOW |
| ALGN |
Guide |
North America Clear Aligner trajectory (commentary) |
UNKNOWN |
pred ~stable/-1% YoY vs. cons hoping ~+1-2% inflection (Q2'26) |
LOW |
| ALGN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
LOW |
| ALGN |
Return |
5-day cumulative residual |
-5.0% (FADE) |
Stock rallied ~5% into the print (167->176), so expectations are elevated. Base case is a clean beat-and-reaffirm rather than the FY guidance raise bulls want; with North America still soft and out-period math implying a heavy 2H margin ramp to hit ~23.7%, a beat-only, no-raise print likely triggers 'sell the news.' Absent a clear NA inflection, revisions drift down and the post-print bounce fades further over the week. High-variance name (ALGN often moves double digits), so confidence is low; a genuine NA re-acceleration or guide raise would flip this to follow-through. |
LOW |